other material
confidence high
sentiment positive
materiality 0.75
X4 reports positive Phase 2 mavorixafor data in chronic neutropenia; starts Phase 3 4WARD trial
X4 Pharmaceuticals, Inc
- 100% (6/6) evaluable participants achieved target ANC increase (>500 cells/µL) at Months 3 and 6 on mavorixafor ± G-CSF.
- Mavorixafor monotherapy achieved mean ANC ≥1,500 cells/µL at Months 3 and 6; severe CN patients had mean ANC ~800-1,000 cells/µL.
- Combination with stable-dose G-CSF increased mean ANC >1,000 cells/µL vs baseline at Months 1, 3, and 6.
- No drug-related serious adverse events; three discontinuations due to non-serious AEs.
- Global Phase 3 4WARD trial initiated (randomized, 150 patients, 52 weeks) for congenital, autoimmune, or idiopathic CN.